RU2014143250A - Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания - Google Patents
Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания Download PDFInfo
- Publication number
- RU2014143250A RU2014143250A RU2014143250A RU2014143250A RU2014143250A RU 2014143250 A RU2014143250 A RU 2014143250A RU 2014143250 A RU2014143250 A RU 2014143250A RU 2014143250 A RU2014143250 A RU 2014143250A RU 2014143250 A RU2014143250 A RU 2014143250A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- optionally
- compound
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 11
- 230000003612 virological effect Effects 0.000 title claims 11
- -1 7-OXO-THIAZOLOPYRIDINE CARBOXYLIC ACID DERIVATIVES Chemical class 0.000 title claims 5
- 238000011282 treatment Methods 0.000 title claims 3
- 230000002265 prevention Effects 0.000 title 1
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 44
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 38
- 150000001875 compounds Chemical class 0.000 claims abstract 29
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 29
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract 15
- 125000005842 heteroatom Chemical group 0.000 claims abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 10
- 229910052799 carbon Inorganic materials 0.000 claims abstract 6
- 229940126523 co-drug Drugs 0.000 claims abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 6
- 239000000203 mixture Substances 0.000 claims abstract 6
- 229940002612 prodrug Drugs 0.000 claims abstract 6
- 239000000651 prodrug Substances 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 239000012453 solvate Substances 0.000 claims abstract 6
- 239000013078 crystal Substances 0.000 claims abstract 3
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 238000000034 method Methods 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 239000003937 drug carrier Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 125000003367 polycyclic group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 4
- 206010022000 influenza Diseases 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 241000712892 Arenaviridae Species 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 3
- 241000711950 Filoviridae Species 0.000 claims 3
- 241000700586 Herpesviridae Species 0.000 claims 3
- 241000712464 Orthomyxoviridae Species 0.000 claims 3
- 241000711504 Paramyxoviridae Species 0.000 claims 3
- 241000150350 Peribunyaviridae Species 0.000 claims 3
- 241000709664 Picornaviridae Species 0.000 claims 3
- 241000712907 Retroviridae Species 0.000 claims 3
- 241000711931 Rhabdoviridae Species 0.000 claims 3
- 241000710781 Flaviviridae Species 0.000 claims 2
- 241000710924 Togaviridae Species 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 101800004538 Bradykinin Proteins 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims 1
- 102100035792 Kininogen-1 Human genes 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims 1
- 229940123066 Polymerase inhibitor Drugs 0.000 claims 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940125400 channel inhibitor Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000002911 sialidase inhibitor Substances 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 230000015572 biosynthetic process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650713P | 2012-05-23 | 2012-05-23 | |
| US61/650,713 | 2012-05-23 | ||
| PCT/EP2013/060633 WO2013174930A2 (en) | 2012-05-23 | 2013-05-23 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014143250A true RU2014143250A (ru) | 2016-07-20 |
Family
ID=48669865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014143250A RU2014143250A (ru) | 2012-05-23 | 2013-05-23 | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9434745B2 (https=) |
| EP (1) | EP2864338B1 (https=) |
| JP (1) | JP2015517555A (https=) |
| KR (1) | KR20150009553A (https=) |
| CN (1) | CN104334563B (https=) |
| BR (1) | BR112014029016A8 (https=) |
| CA (1) | CA2874250A1 (https=) |
| ES (1) | ES2617861T3 (https=) |
| MX (1) | MX2014014106A (https=) |
| RU (1) | RU2014143250A (https=) |
| WO (1) | WO2013174930A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US20130317021A1 (en) * | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
| US20140010783A1 (en) * | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| WO2014143242A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| WO2016005330A1 (en) | 2014-07-07 | 2016-01-14 | F. Hoffmann-La Roche Ag | Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases |
| BR112017022550B1 (pt) | 2015-04-28 | 2021-02-23 | Shionogi & Co., Ltd | derivados policíclicos de piridona substituída |
| MX394421B (es) | 2015-04-28 | 2025-03-24 | Shionogi & Co | Derivados de piridona policiclica sustituida y profarmaco de los mismos |
| US20170081331A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| AU2016374416A1 (en) | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| EP3478671B1 (en) | 2016-06-29 | 2020-05-13 | H. Hoffnabb-La Roche Ag | Pyridazinone-based broad spectrum anti-influenza inhibitors |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| MX2020002869A (es) | 2017-09-15 | 2020-07-24 | Aduro Biotech Inc | Compuestos de pirazolopirimidinona y usos de los mismos. |
| CN117304133B (zh) * | 2023-09-26 | 2026-03-17 | 华南农业大学 | 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| EP0927164A1 (en) * | 1996-09-10 | 1999-07-07 | PHARMACIA & UPJOHN COMPANY | 8-hydroxy-7-substituted quinolines as anti-viral agents |
| DE69831506T2 (de) * | 1997-12-22 | 2006-06-29 | Pharmacia & Upjohn Co. Llc, Kalamazoo | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe |
| US6559145B2 (en) * | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
| AU2003262946A1 (en) | 2002-08-30 | 2004-03-19 | Pharmacia And Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
| CN101014572B (zh) | 2004-09-15 | 2011-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| US20130317021A1 (en) * | 2012-05-23 | 2013-11-28 | Savira Pharmaceuticals Gmbh | Heterocyclic pyrimidine carbonic acid derivatives which are useful in the treatment, amelioration or prevention of a viral disease |
-
2013
- 2013-05-23 RU RU2014143250A patent/RU2014143250A/ru not_active Application Discontinuation
- 2013-05-23 MX MX2014014106A patent/MX2014014106A/es unknown
- 2013-05-23 JP JP2015513182A patent/JP2015517555A/ja active Pending
- 2013-05-23 WO PCT/EP2013/060633 patent/WO2013174930A2/en not_active Ceased
- 2013-05-23 KR KR1020147032703A patent/KR20150009553A/ko not_active Withdrawn
- 2013-05-23 BR BR112014029016A patent/BR112014029016A8/pt not_active IP Right Cessation
- 2013-05-23 CA CA2874250A patent/CA2874250A1/en not_active Abandoned
- 2013-05-23 ES ES13730130.5T patent/ES2617861T3/es active Active
- 2013-05-23 US US13/900,964 patent/US9434745B2/en not_active Expired - Fee Related
- 2013-05-23 CN CN201380025120.0A patent/CN104334563B/zh not_active Expired - Fee Related
- 2013-05-23 EP EP13730130.5A patent/EP2864338B1/en not_active Not-in-force
-
2016
- 2016-08-26 US US15/247,991 patent/US20160362423A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN104334563B (zh) | 2017-03-08 |
| ES2617861T3 (es) | 2017-06-20 |
| US9434745B2 (en) | 2016-09-06 |
| BR112014029016A2 (pt) | 2017-06-27 |
| WO2013174930A3 (en) | 2014-01-23 |
| KR20150009553A (ko) | 2015-01-26 |
| CN104334563A (zh) | 2015-02-04 |
| WO2013174930A2 (en) | 2013-11-28 |
| MX2014014106A (es) | 2015-09-25 |
| JP2015517555A (ja) | 2015-06-22 |
| EP2864338A2 (en) | 2015-04-29 |
| EP2864338B1 (en) | 2016-12-14 |
| CA2874250A1 (en) | 2013-11-28 |
| HK1205128A1 (en) | 2015-12-11 |
| BR112014029016A8 (pt) | 2018-01-09 |
| US20130317022A1 (en) | 2013-11-28 |
| US20160362423A1 (en) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014143250A (ru) | Производные 7-оксо-тиазолопиридин карбоновой кислоты и их применение при лечении, облегчении или профилактике вирусного заболевания | |
| RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
| RU2014146778A (ru) | Производные 7-оксо-4,7-дигидропиразоло[1,5-а]пиримидина, которые пригодны для лечения, уменьшения интенсивности или предупреждения вирусного заболевания | |
| JP2015517555A5 (https=) | ||
| JP2015521189A5 (https=) | ||
| JP2016518305A5 (https=) | ||
| RU2014120421A (ru) | Производные гетероарилгидроксамовой кислоты и их применение при лечении, облегчении течения или профилактике вирусных заболеваний | |
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2016508145A5 (https=) | ||
| JP2015509983A5 (https=) | ||
| JP2017518959A5 (https=) | ||
| CN109328187A (zh) | 一种具有fgfr抑制活性的新型化合物及其制备和应用 | |
| JP2013010792A5 (https=) | ||
| BR112013024059A2 (pt) | compostos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| JP2016509047A5 (https=) | ||
| BR112014019478A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença. | |
| JP2014500295A5 (https=) | ||
| RU2013119129A (ru) | Органические соединения | |
| RU2014113539A (ru) | Тетрациклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
| RU2014120477A (ru) | Производные пиримидин-4-она и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| RU2015125570A (ru) | Пиридоновые производные и их применение в лечении, уменьшении интенсивности симптомов или предотвращении вирусного заболевания | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2008107733A (ru) | Ингибиторы gsk-3 | |
| JP2015535247A5 (https=) | ||
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170926 |